Account Management LLC Has $1.05 Million Stake in Zoetis Inc. (NYSE:ZTS)

Account Management LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,305 shares of the company’s stock after selling 170 shares during the period. Zoetis comprises 1.3% of Account Management LLC’s portfolio, making the stock its 15th largest holding. Account Management LLC’s holdings in Zoetis were worth $1,047,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC increased its holdings in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky boosted its position in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Moisand Fitzgerald Tamayo LLC boosted its position in Zoetis by 105.5% during the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares during the period. Ramirez Asset Management Inc. bought a new stake in Zoetis during the third quarter worth approximately $35,000. Finally, First Financial Corp IN boosted its position in Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after purchasing an additional 79 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS traded up $5.06 during mid-day trading on Friday, hitting $158.42. The company’s stock had a trading volume of 5,236,463 shares, compared to its average volume of 4,019,007. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The firm has a market capitalization of $72.45 billion, a PE ratio of 31.25, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. The stock’s 50-day moving average is $171.79 and its two-hundred day moving average is $179.31.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 earnings per share. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.09%. Zoetis’s payout ratio is 34.12%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock worth $371,293. 0.12% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZTS. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. The Goldman Sachs Group upped their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Stifel Nicolaus reduced their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Finally, Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $218.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.